Prognostic Implications of Primary Tumor Resection in Stage IVB Colorectal Cancer in Elderly Patients

Heui-June Ahn, Ho-Suk Oh, Yongchel Ahn, Sang Jin Lee, Hyun Joong Kim, Moon Ho Kim, Dae-Woon Eom, Jae Young Kwak, Myoung Sik Han, Jae Seok Song

Departments of Internal Medicine, Pathology, and Surgery, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung; Department of Preventive Medicine, Kwandong University College of Medicine, Gangneung, Korea

Purpose: The aim of this study was to identify prognostic factors in stage IVB colorectal cancer in elderly patients, focusing on the influence of treatment modalities, including palliative chemotherapy and primary tumor resection.

Methods: A cohort of 64 patients aged over 65 years who presented with stage IVB colorectal cancer at the Gangneung Asan Hospital between July 1, 2001, and December 31, 2009, was analyzed. Demographics, tumor location, tumor grade, performance status, levels of carcinoembryonic antigen (CEA), level of aspartate aminotransferase (AST), and distant metastatic site at diagnosis were analyzed. Using the treatment histories, we analyzed the prognostic implications of palliative chemotherapy and surgical resection of the primary tumor retrospectively.

Results: The cohort consisted of 30 male (46.9%) and 34 female patients (53.1%); the median age was 76.5 years. Primary tumor resection was done on 28 patients (43.8%); 36 patients (56.2%) were categorized in the nonresection group. The median survival times were 12.43 months in the resection group and 3.58 months in the nonresection group (P < 0.001). Gender, level of CEA, level of AST, Eastern Cooperative Oncology Group performance status, tumor location, and presence of liver metastasis also showed significant differences in overall survival. On multivariate analysis, male gender, higher level of CEA, higher AST level, and no primary tumor resection were independent poor prognostic factors. In particular, nonresection of the primary tumor was the most potent/poor prognostic factor in the elderly-patient study group (P = 0.001; 95% confidence interval, 2.33 to 21.99; hazard ratio, 7.16).

Conclusion: In stage IVB colorectal cancer in elderly patients, resection of the primary tumor may enhance survival.

Keywords: Colorectal neoplasms; Prognosis; Palliative surgery

INTRODUCTION

Almost 150,000 new cases of colorectal cancer are diagnosed every year, and it is the second leading cause of cancer death in the United States, being responsible for nearly 50,000 deaths per year [1]. In Korea, colorectal cancer makes up 12.7% of all malignant diseases, and it is the fourth most common cause of cancer-related death [2]. Moreover, the incidence and the mortality of this disease have increased in recent years [3].

Recently, we have faced changes to the standards and classifications in the management of cancer patients. Since January 1, 2010, the seventh edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual has been used as the standard for the staging of all new cancer cases. In this standard, stage IV colorectal cancer has been subdivided into stage IVA and IVB, as determined by the pattern of distant metastasis. Stage IVA (M1a) is defined as single metastatic site/organ, and IVB (M1b) is defined as more than one organ/site or seeding of the peritoneum.

Another change compared to past decades is the increasing proportion of elderly patients due to life extension. Deciding the
treatment plan for elderly cancer patients is more difficult due to the higher levels of physical and psychological stress. In addition, because most elderly patients are excluded from clinical trials due to strict inclusion criteria and ethical problems, standard treatments are not necessarily suitable for uniform application. Hence, in the choice of treatment in these elderly stage IVB colorectal patients, whether surgical removal of the primary lesion will enhance the survival rate or not is still debatable [4-9]. Despite the increasing importance of this population, evaluation of the prognostic factors of stage IVB colorectal cancer in the elderly remains unreported. Therefore, the present study evaluated the prognostic factors for elderly stage IVB patients by performing a retrospective analysis. The analysis focused on the treatment modality, including palliative chemotherapy and primary tumor resection, used for elderly colorectal stage IVB patients. The main aim of this study is to help determine the optimal treatment modality by comparing survival rates attained by using various treatment modalities for elderly patients with stage IVB colorectal cancer.

METHODS

Participants and materials
The authors identified 226 patients over 65 years of age who were pathologically diagnosed with stage IV colorectal cancer, according to the AJCC Cancer Staging Manual (6th edition), at the Gangneung Asan Hospital from July 1, 2001, to December 31, 2009. Each tumor stage was recategorized as M1a (metastasis confined to one organ or site) or M1b (metastases in more than one organ/site or the peritoneum) according to the AJCC Cancer Staging Manual (7th edition). Sixty-four stage IVB patients were analyzed in this study. All the patients’ pathologic findings indicated an adenocarcinoma. The median follow-up duration was 5.29 months (maximum duration, 36 months). The cancer-specific data for each patient contained the tumor location, tumor grade, performance status, level of carcinoembryonic antigen (CEA), level of aspartate aminotransferase (AST), metastatic sites, and treatment modalities. Tumor location was categorized as ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, left colon, sigmoid colon, and rectum, which were recategorized into three groups: right-side colon, left-side colon, and rectum. Tumors were categorized as low grade (well-to-moderately differentiated) or high grade (poorly differentiated). Performance status was defined according to the Eastern Cooperative Oncology Group (ECOG) guidelines. Levels of CEA and AST at diagnosis were analyzed. Distant metastatic sites were categorized in terms of the presence of liver, lung, peritoneum, and nonregional lymph nodes at diagnosis. From the treatment histories, palliative chemotherapy and surgical resection of the primary tumor or its absence were evaluated. This study was approved by the Institutional Review Board of Gangneung Asan Hospital of the University of Ulsan’s College of Medicine (No. 2013-039).

Statistical analysis
The descriptive statistics were calculated, including the means and medians or the counts and percentages. Survival data based on the above-recorded variables were computed according to the Kaplan–Meir method, and the curves were compared using a log-rank test. Overall survival (OS) was measured from the date of the diagnosis to the last follow-up or death. Differences were considered statistically significant when the P-value was <0.05. Finally, a multivariate analysis was performed using the Cox proportions hazards model to assess the influence of the above prognostic factors on OS; again, statistical significance was set at P-value <0.05. All statistical analyses were performed using PASW Statistics ver. 18.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

Patients’ characteristics
A total of 64 patients participated in this analysis, 30 male (46.9%) and 34 female patients (53.1%), with a median age of 76.5 years. We described the baseline characteristics of all the enrolled patients in Table 1. The anatomical location of the primary tumor was specified. Among all patients, 20 patients (31.3%) had tumors in the right colon (cecum, ascending colon, hepatic flexure, and transverse colon), 28 patients (43.7%) had tumors in the left colon (splenic flexure, descending, sigmoid colon), and 16 patients (25.0%) had tumors in the rectum. Liver metastasis was shown in 38 patients (59.4%), lung metastasis was shown in 20 patients (31.3%), seeding of the peritoneum was shown in 32 patients (50.0%), and nonregional lymph node metastasis was shown in eight patients (12.5%). Among all the patients in the cohort, 44 patients (68.7%) had low-grade tumors, and 20 patients (31.3%) had high-grade tumors.

Treatment modalities
Primary tumor resection was done in 28 patients (43.8%). Among them, 16 patients received an emergency surgical resection due to obstruction by the tumor, and two patients received the procedure due to perforation. Of the remaining ten patients, surgery was performed with an elective palliative aim due to an obstructive symptom. Of the 18 emergency resection patients, five Hartmann’s operations, three right hemicolecotomies, three abdominoperineal resections, three ileocecal resections, two left hemicolecotomies, one total colectomy, and one anterior resection were conducted. Of the 10 elective resection patients, five right hemicolecotomies, three low anterior resections, and two anterior resections were conducted. No patient underwent a metastasectomy in either group. In the nonresection group, two patients underwent an emergency colostomy, and four patients had stents inserted due to obstruction at diagnosis.

Other clinicopathological factors were not different between the nonresection and the resection groups (Table 2). Thirty patients (46.9%) received palliative chemotherapy. Of the 36 nonresection
patients, 14 patients (38.9%) received chemotherapy; among the 28 resection patients, 16 patients (57.6%) received it. Thirty-four patients did not receive chemotherapy, the reasons for which were refusal of treatment, poor performance and general weakness, and family members’ choice. Among the 30 patients treated with palliative chemotherapy, most underwent 5-fluorouracil (FU)-based combination chemotherapy with oxaliplatin or irinotecan; 17 patients (56.7%) were treated with oxaliplatin combined with oxaliplatin (FOLFOX) as the first-line chemotherapy, six patients (20%) were treated with 5-fluorouracil plus leukovorin chemotherapy, three patients (10%) were treated with 5-FU-based combination chemotherapy with irinotecan (FOLFIRI), and four patients (13.3%) were treated with a capecitabine single regimen according to the clinician’s decision. After first-line chemotherapy, eight patients underwent second-line chemotherapy, where four cases each were treated with FOLFOX and FOLFIRI regimens. The mean numbers of cycles of first-line and second-line chemotherapy were 3.92 cycles (2–8 cycles) and 1.5 cycles (1 or 2 cycles), respectively. There were no patients treated with third-line chemotherapy.

Analysis of the prognosis factors and the survival rate
The median survival time was 12.43 months in the resection group and 3.58 months in the nonresection group (P < 0.001) (Table 3, Fig. 1A). In addition, gender, level of CEA, level of AST, ECOG performance status, tumor location, and presence of liver metastasis showed significant differences in OS. The results of the univariate analysis of OS are shown in Table 2 and Fig. 1B-D.

In the multivariate analysis using the Cox proportional hazards model, male gender, higher level of CEA, higher AST level, and no primary tumor resection were independent poor prognostic factors. In particular, absence of primary tumor resection was the most potent risk factor in these elderly patients (P = 0.001; 95% confidence interval [CI], 2.33 to 21.99; hazard ratio: 7.16) (Table 3). However, histologic grade and presence of liver metastasis were not independent predictive factors of OS (Table 4). Primary tumor location and ECOG performance status influenced primary tumor resection; tumors with right-sided and rectal origins more frequently underwent a primary tumor resection, and patients with good performance status had a greater chance of undergoing primary tumor resection.

DISCUSSION

Prognostic implications of clinicopathologic features have been extensively studied in the earlier stages of colon cancer (I–III) that undergo resection. However, few studies have evaluated prognostic factors in patients with incurable metastatic colon cancer, especially the influence of primary tumor resection [4, 10]. In particular, elderly patients have a bad condition overall, with various underlying diseases, and whether surgical removal of the primary lesion will enhance the survival rate for these patients is still de-

Table 1. Baseline characteristics of the patients (n=64)

| Characteristic                        | No. (%)
|--------------------------------------|---------------------
| Gender                               |                     |
| Male                                 | 30 (46.9)           |
| Female                               | 34 (53.1)           |
| Age (yr)                             |                     |
| ≥65, <70                             | 14 (21.9)           |
| ≤70, <75                             | 16 (25.0)           |
| ≥75                                  | 34 (53.1)           |
| Location                             |                     |
| Right side colon                     | 20 (31.3)           |
| Left side colon                      | 28 (43.7)           |
| Rectum                               | 16 (25.0)           |
| Histologic grade                     |                     |
| Low grade (well-to-moderately differentiated) | 44 (68.7) |
| High grade (poorly differentiated)   | 20 (31.3)           |
| CEA level*                           |                     |
| <25                                  | 22 (47.8)           |
| ≥25, <50                             | 6 (13.0)            |
| ≥50                                  | 18 (39.2)           |
| ECOG performance status              |                     |
| 1                                    | 12 (18.8)           |
| 2                                    | 36 (56.2)           |
| 3                                    | 16 (25.0)           |
| AST level                            |                     |
| <40                                  | 46 (71.9)           |
| ≥40                                  | 18 (28.1)           |
| Presence of liver metastasis         |                     |
| No                                   | 26 (40.6)           |
| Yes                                  | 38 (59.4)           |
| Presence of lung metastasis          |                     |
| No                                   | 44 (68.7)           |
| Yes                                  | 20 (31.3)           |
| Presence of peritoneal metastasis    |                     |
| No                                   | 32 (50.0)           |
| Yes                                  | 32 (50.0)           |
| Presence of nonregional LNs metastasis |                   |
| No                                   | 56 (87.5)           |
| Yes                                  | 8 (12.5)            |
| Primary tumor resection              |                     |
| No                                   | 36 (56.2)           |
| Yes                                  | 28 (43.8)           |
| Palliative chemotherapy              |                     |
| Not done                             | 34 (53.1)           |
| Done                                 | 30 (46.9)           |

CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; AST, aspartate aminotransferase; LN, lymph node.

*CEA level data were available in 48 cases out of 64.
Table 2. Differences in clinical parameters according to primary tumor resection or not

| Variable                          | Primary tumor resection | P-value* |
|-----------------------------------|-------------------------|---------|
|                                   | Not done | Done |       |
| Gender                           |           |      | 0.092 |
| Male                             | 20 (66.7) | 10 (33.3) |       |
| Female                           | 16 (47.1) | 18 (52.9) |       |
| Age (yr)                         |           |      | 0.839 |
| ≥65, <70                         | 8 (57.1) | 6 (42.9) |       |
| ≤70, <75                         | 8 (50.0) | 8 (50.0) |       |
| ≥75                              | 20 (58.8) | 14 (41.2) |       |
| Location                         |           |      | 0.006 |
| Right side colon                 | 8 (40.0) | 12 (60.0) |       |
| Left side colon                  | 22 (78.6) | 6 (21.4) |       |
| Rectum                           | 6 (37.5) | 10 (62.5) |       |
| Histologic grade                 |           |      | 0.110 |
| Low grade (well-to-moderately differentiated) | 22 (50.0) | 22 (50.0) |       |
| High grade (poorly differentiated) | 14 (70.0) | 6 (30.0) |       |
| CEA level                        |           |      | 0.061 |
| <25                              | 9 (40.9) | 13 (59.1) |       |
| ≥25, <50                         | 3 (50.0) | 3 (50.0) |       |
| ≥50                              | 14 (77.8) | 4 (22.2) |       |
| AST level                        |           |      | 0.221 |
| <40                              | 24 (52.2) | 22 (47.8) |       |
| ≥40                              | 12 (66.7) | 6 (33.3) |       |
| Presence of liver metastasis     |           |      | 0.138 |
| No                               | 12 (46.2) | 14 (53.8) |       |
| Yes                              | 24 (63.2) | 14 (36.8) |       |
| Presence of lung metastasis      |           |      | 0.110 |
| No                               | 22 (50.0) | 22 (50.0) |       |
| Yes                              | 14 (70.0) | 6 (30.0) |       |
| Presence of peritoneal metastasis|           |      | 0.599 |
| No                               | 18 (56.3) | 14 (43.7) |       |
| Yes                              | 18 (56.3) | 14 (43.7) |       |
| Presence of nonregional LNs metastasis | 32 (57.1) | 24 (42.9) |       |
| No                               | 4 (50.0) | 4 (50.0) |       |
| ECOG performance status          |           |      | 0.001 |
| 1                                | 2 (16.7) | 10 (83.3) |       |
| 2                                | 20 (55.6) | 16 (44.4) |       |
| 3                                | 14 (87.5) | 2 (12.5) |       |
| Palliative chemotherapy           |           |      | 0.115 |
| Not done                         | 22 (64.7) | 12 (35.3) |       |
| Done                             | 14 (46.7) | 16 (53.3) |       |

Values are presented as number (%).
CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; AST, aspartate aminotransferase.
*Chi-square.

Table 3. Univariate analysis of overall survival (n=64)

| Variable                          | No. (%) | Median survival (mo) | 95% CI | P-value |
|-----------------------------------|---------|----------------------|--------|---------|
| Gender                           |         |                      |        | 0.041   |
| Male                             | 30 (46.9) | 2.83 | 1.37–4.28 |       |
| Female                           | 34 (53.1) | 10.08 | 5.68–14.49 |       |
| Age (yr)                         |         |                      |        | 0.286   |
| ≥65, <70                         | 14 (21.9) | 5.25 | 2.33–8.17 |       |
| ≤70, <75                         | 16 (25.0) | 11.09 | 7.42–14.76 |       |
| ≥75                              | 34 (53.1) | 3.83 | 1.39–6.26 |       |
| Location                         |         |                      |        | 0.005   |
| Right side colon                 | 20 (31.3) | 11.96 | 9.19–14.73 |       |
| Left side colon                  | 28 (43.7) | 3.48 | 2.41–4.55 |       |
| Rectum                           | 16 (25.0) | 7.85 | 6.97–8.73 |       |
| Histologic grade                 |         |                      |        | 0.124   |
| Low grade (well-to-moderately differentiated) | 44 (68.7) | 5.49 | 1.27–2.99 |       |
| High grade (poorly differentiated) | 20 (31.3) | 3.82 | 0.05–3.72 |       |
| CEA level*                       |         |                      |        | 0.000   |
| <25                              | 22 (47.8) | 13.60 | 8.53–18.67 |       |
| ≥25, <50                         | 6 (13.0) | 6.16 | 0.00–13.89 |       |
| ≥50                              | 18 (39.2) | 2.83 | 0.99–4.66 |       |
| ECOG performance status          |         |                      |        | 0.004   |
| 1                                | 12 (18.8) | 11.96 | 8.56–15.35 |       |
| 2                                | 36 (56.2) | 5.29 | 0.23–5.73 |       |
| 3                                | 16 (25.0) | 1.96 | 0.15–3.76 |       |
| AST level                        |         |                      |        | 0.001   |
| <40                              | 46 (71.9) | 7.55 | 3.55–11.56 |       |
| ≥40                              | 18 (28.1) | 2.83 | 0.96–4.69 |       |
| Presence of liver metastasis     |         |                      |        | 0.036   |
| No                               | 26 (40.6) | 11.09 | 8.74–13.43 |       |
| Yes                              | 38 (59.4) | 5.19 | 2.63–7.69 |       |
| Presence of lung metastasis      |         |                      |        | 0.087   |
| No                               | 44 (68.7) | 5.49 | 0.18–10.79 |       |
| Yes                              | 20 (31.3) | 3.96 | 0.77–7.18 |       |
| Presence of peritoneal metastasis|         |                      |        | 0.601   |
| No                               | 32 (50.0) | 5.39 | 4.04–6.73 |       |
| Yes                              | 32 (50.0) | 3.83 | 1.45–6.19 |       |
| Presence of nonregional LNs metastasis | 56 (87.5) | 5.29 | 4.69–5.89 |       |
| No                               | 8 (12.5) | 3.69 | 0.00–9.06 |       |
| Primary tumor resection          |         |                      |        | 0.000   |
| No                               | 36 (56.3) | 3.58 | 2.34–4.81 |       |
| Yes                              | 28 (43.7) | 12.43 | 9.38–15.49 |       |
| Palliative chemotherapy           |         |                      |        | 0.158   |
| Not done                         | 34 (53.1) | 3.48 | 2.06–4.91 |       |
| Done                             | 30 (46.9) | 10.09 | 5.34–14.83 |       |

Values are presented as number (%).
CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; AST, aspartate aminotransferase.

*CEA level data were available in 46 cases out of 64.
batable [4-9]. In general, nonoperative methods—chemotherapy, stent insertion, and bypass—are used in patients with incurable disease. A number of studies have reported that in the case of chemotherapy, the median survival period and the OS rate can be increased by using a single treatment modality without removing the primary lesion [11-13]. However, there is a lack of randomized controlled trials demonstrating the prognostic impact of resection of the primary colon tumor in the setting of metastatic disease. Generally, treatment decisions regarding the primary colon tumor in the metastatic setting are guided by the presence or absence of symptoms and whether or not the metastases are resectable. If patients present with symptomatic primary tumors (bleeding, obstruction, or perforation), they are considered for either a palliative resection or for the placement of a colonic stent to help relieve an obstruction, followed by systemic chemotherapy if tolerable. However, elderly patients also have difficulties in being treated with palliative chemotherapy due to the comorbidities and poor performance status, considering the relatively long-term treatment periods involved in palliative chemotherapy. In practice, larger proportions of elderly patients give up on the treat-

Fig. 1. Kaplan-Meir estimates of overall survival according to primary tumor resection (A), carcinoembryonic antigen (CEA) level (B), gender (C), and level of aspartate aminotransferase (AST) (D) in elderly stage IVB colorectal cancer.
Table 4. Multivariate analysis of possible prognostic factors

| Variable                        | Hazard ratio | 95% CI      | P-value |
|---------------------------------|--------------|-------------|---------|
| Male gender                     | 3.92         | 1.55–9.92   | 0.004   |
| High grade                      | 2.03         | 0.86–4.79   | 0.104   |
| High CEA level                  | 2.48         | 1.45–4.23   | 0.001   |
| High AST level                  | 3.64         | 1.48–8.99   | 0.005   |
| No primary tumor resection      | 7.16         | 2.33–21.99  | 0.001   |
| Presence of liver metastasis   | 2.57         | 0.99–6.63   | 0.052   |

CI, confidence interval; CEA, carcinoembryonic antigen; AST, aspartate aminotransferase.

Previous studies reported an acceptable range of complications after surgical resection of the primary lesion, with 16.2% (17/105) as the postoperative major complication rate and 2.86% (3/105) as the postoperative death rate [9, 17]. In this study, no patient suffered postoperative death within one month, but two deaths occurred within two months. Even though the group was elderly and underwent frequent emergency operations, outcomes showed an acceptable postoperative mortality rate. This could be explained by the highly developed perioperative adjunctive care given to the patients and the highly selective indications used by the clinicians.

Tumor location may also influence the surgical outcome for elderly patients. The present study observed that patients with right colon cancer had significantly more advanced cancer stages than patients with left colon cancer, in accordance with a previous systematic literature review. In 1990, Bufill [18] was the first to propose that colon cancer located on either the right or the left side of the colon may arise from different biological pathways. Furthermore, right colon cancer and left colon cancer also differ in terms of patient characteristics, pathology, and prognosis [19]. A recent systematic review of the sparse literature on the topic supports the existence of such differences [20]. In a previous study, the present authors observed an almost linear relationship between tumor location and age; that is, the more proximally the tumor was located, the higher was the median age of the patients [21]. The present findings also showed a relatively higher incidence of right-sided colon cancer than in a general population. Eventually, right-sided colon cancer showed a higher rate of primary tumor resection than left-sided colon cancer. Even though right-sided colon cancer, with its poorer prognosis, showed longer median survival than left-sided colon cancer in the univariate analysis, this was not significant in the multivariate analysis in the present study of elderly patients.

The reason for the low rate of stent insertion, which is expected to develop fewer complications, may be that right-sided obstructive lesions have limited indications due to abdominal discomfort after stent insertion. In addition, the higher frequency of a right-sided obstruction in elderly patients influenced the poorer tolerability and compliance with the endoscopic procedure without general anesthesia. According to the findings of the current study, elderly stage IVB patients have different clinical disease situations compared to relatively younger patients; thus, special consideration is needed for the best treatment choice.

In conclusion, this study is too limited to be generalized to all elderly stage IVB colorectal cancer patients. Nevertheless, when patients are carefully selected, resection of the primary lesion may enhance the survival of patients.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.
REFERENCES

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. National Cancer Information Center [Internet]. Goyang: National Cancer Information Center; c2012 [cited 2013 Jan 26]. Available from: http://www.cancer.go.kr.
3. Shin HR, Jung KW, Won YJ, Park JG; 139 KCCR-affiliated Hospitals. 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 2004;36:103-14.
4. Luo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 2003;196:722-8.
5. Makela J, Hautipuro K, Laitinen S, Kairaluoma MI. Palliative operations for colorectal cancer. Dis Colon Rectum 1990;33:846-50.
6. Liu SK, Church JM, Lavery IC, Fazio VW. Operation in patients with incurable colon cancer—is it worthwhile? Dis Colon Rectum 1997;40:11-4.
7. Beham A, Rentisch M, Pullmann K, Mantouvalou L, Spatz H, Schlitt H, et al. Survival benefit in patients after palliative resection vs non-resection colon cancer surgery. World J Gastroenterol 2006;12:6634-8.
8. Costi R, Mazzeo A, Di Mauro D, Veronesi L, Sansebastiano G, Violi V, et al. Palliative resection of colorectal cancer: does it prolong survival? Ann Surg Oncol 2007;14:2567-76.
9. Kleepees A, Fussl KE, Seeliger H, Eichhorn ME, Muller MH, Rentisch M, et al. Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis 2009;24:1097-109.
10. Yun HR, Lee WY, Lee WS, Cho YB, Yun SH, Chun HK. The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient’s status. Int J Colorectal Dis 2007;22:1301-10.
11. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
12. de Gramont A, Figer A, Seymour M, Homorin M, Hmissi A, Cassidy J, et al. Bevacizumab and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
14. Zacharakis M, Xynos ID, Lazaris A, Smaro C, Kosmas C, Dokou A, et al. Predictors of survival in stage IV metastatic colorectal cancer. Anticancer Res 2010;30:653-60.
15. Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 2005;89:211-7.
16. Kim JH, Shon DH, Chung BI, Chung MK, Shim MC. Complete single stage management of left colon cancer obstruction with a new devices. J Korean Soc Coloproctol 2002;18:30-6.
17. Kim SK, Lee CH, Lee MR, Kim JH. Multivariate analysis of the survival rate for treatment modalities in incurable stage IV colorectal cancer. J Korean Soc Coloproctol 2012;28:35-41.
18. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113:779-88.
19. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010;53:57-64.
20. Hansen IO, Jess P. Possible better long-term survival in left versus right-sided colon cancer: a systematic review. Dan Med J 2012;59:A4444.
21. Jess P, Hansen IO, Gamborg M, Jess T; Danish Colorectal Cancer Group. A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open 2013;3:e002608.